Sudeep Pharma Share Price Gains Strongly; IPO Lists at ₹730 With a Premium of 23.10% Over Issue Price of ₹593

Vadodara, November 28: Sudeep Pharma IPO has made a stellar listing on stock exchanges today, on November 28. The shares of Sudeep Pharma listed at ₹730 per share, against an issue price of ₹593 per share. The listing marks a premium of 23.10% over the issue price. As of 11:30 AM, the shares were up by 32.02%, or 189.95 points, and were trading at ₹782.85. Until now, the shares have traded within a range of ₹793.30 and ₹725. The traded volume stood at 2.54 crore shares.

Sudeep Pharma IPO Key Details

The ₹895 crore Sudeep Pharma IPO was a combination of a fresh issue of 0.16 crore shares aggregating to ₹95 crores and an offer for sale of 1.35 crore shares aggregating to ₹800 crores. Sudeep Pharma’s IPO price band was at ₹562 to ₹593 per share. The lot size was 25 shares per application, with a minimum investment amount by a retail investor at ₹14,825 (25 shares) at the upper price band. ICICI Securities Ltd. was the book-running lead manager, and MUFG Intime India Pvt.Ltd was the registrar of the issue.

Sudeep Pharma IPO Subscription Status Highlights

Sudeep Pharma’s IPO witnessed robust demand, being oversubscribed by 93.71 times overall. Qualified Institutional Buyers (QIBs) led the subscription at 213.08 times, followed by Non-Institutional Buyers at 116.72 times, while retail investors contributed a 15.65 times subscription.

Sudeep Pharma IPO: Anchor Allocation

Ahead of the IPO, Sudeep Pharma raised ₹268.5 crore from anchor investors by allocating them 45,27,823 shares at ₹593 per share. Key investors included SBI Mutual Fund (MF), HDFC MF, ICICI Prudential MF, Nippon India MF, WhiteOak Capital MF, Aditya Birla Sun Life MF, Motilal Oswal MF, Quant MF, Bandhan MF, UTI MF, Edelweiss MF, Tata AIA Life Insurance and SBI Life Insurance.

Investor Takeaway

Sudeep Pharma’s IPO listed at a premium of 23.10% and was trading up 32.02% as of 11:30 AM. The strong listing follows an overwhelming subscription, with the IPO being oversubscribed 93.71 times across investor categories. The shares continue to see positive demand in the market, reflecting the broad interest generated during the IPO process, while market participants observe how the stock performs in the coming week.

REF:

https://www.nseindia.com/get-quotes/equity?symbol=SUDEEPPHRM

https://www.bseindia.com/stock-share-price/sudeep-pharma-ltd/sudeepphrm/544619/

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations